CoChat
Sign Up
Cited by 311Bone health and osteoporosis researchBone Metabolism and DiseasesBone health and treatments

Secondary Causes of Osteoporosis

Open access
FITZPATRICK, LORRAINE A.·2002·Mayo Clinic Proceedings
DOI 10.1016/s0025-6196(11)62214-3
Open this paper in CoChat — free accountOpen PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0025-6196(11)62214-3

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some pituitary diseases can influence bone mineral density and bone turnover, causing osteopenia, osteoporosis, and fractures.

    “Some pituitary diseases may influence bone mineral density (BMD) and bone turnover causing osteopenia, osteoporosis, and fractures [2].”

    From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [2]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 92

  1. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am. 1998;27:349-367.
  2. Haden ST, Fuleihan GE, Angell JE, Cotran NM, LeBoff MS. Calcidiol and PTH levels in women attending an osteoporosis program. Calcif Tissue Int. 1999;64:275-279.
  3. Peris P, Guanabens N, Monegal A, et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. 1995;34:936- 941.
  4. Scane AC, Sutcliffe AM, Francis RM. Osteoporosis in men. Baillieres Clin Rheumatol. 1993;7:589-601.
  5. Caplan GA, Scane AC, Francis RM. Pathogenesis of vertebral crush fractures in women. J R Soc Med. 1994;87:200-202.
  6. Kelepouris N, Harper KD, Gannon F, Kaplan FS, Haddad JG. Severe osteoporosis in men. Ann Intern Med. 1995;123:452-460.
  7. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
  8. Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: sum- mary of a workshop. J Clin Endocrinol Metab. 2001;86:5681- 5685.
  9. Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:279-298.
  10. McKenzie R, Reynolds JC, O'Fallon A, et al. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol. 2000;27: 2222-2226.
  11. Michel GA, Bloch DA, Wolfe F, Fried JF. Fractures in rheuma- toid arthritis: an evaluation of associated risk factors. J Rheu- matol. 1993;20:1666-1669.
  12. Centrella M, Casinghino S, McCarthy TL. Differential actions of prostaglandins in separate cell populations from fetal rat bone. Endocrinology. 1994;135:1611-1620.
  13. Raisz LG, Koolemans-Beynen AR. Inhibition of bone collagen synthesis by prostaglandin E2 in organ culture. Prostaglandins. 1974;8:377-385.
  14. McCarthy TL, Ji C, Casinghino S, Centrella M. Alternate signal- ing pathways selectively regulate binding of insulin-like growth factor I and II on fetal rat bone cells. J Cell Biochem. 1998;68: 446-456.
  15. Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab. 2000;11:79-85.
  16. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteo- cytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85:2907-2912.
  17. American College of Rheumatology Ad Hoc Committee on Glu- cocorticoid-Induced Osteoporosis. Recommendations for the pre- vention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503.
  18. Lukert BP. Glucocorticoid-induced osteoporosis. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, Pa: Lippincott Wil- liams & Wilkins; 1999:292-296.
  19. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticoste- roid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997;61:382-385.
  20. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:382-387.
  21. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypro- pylidene)-1, 1-bisphosphonate (APD). Lancet. 1988;1:143-146.
  22. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202- 211.
  23. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
  24. Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J. 1970;4: 69-72.
  25. Hunter J, Maxwell JD, Stewart DA, Parsons V, Williams R. Altered calcium metabolism in epileptic children on anticonvul- sants. Br Med J. 1971;4:202-204.
  26. Pylypchuk G, Oreopoulos DG, Wilson DR, et al. Calcium me- tabolism in adult outpatients with epilepsy receiving long-term anticonvulsant therapy. Can Med Assoc J. 1978;118:635-638.
  27. Ashworth B, Horn DB. Evidence of osteomalacia in an outpatient group of adult epileptics. Epilepsia. 1977;18:37-43.
  28. Matheson RT, Herbst JJ, Jubiz W, Freston JW, Tolman KG. Absorption and biotransformation of cholecalciferol in drug-in- duced osteomalacia. J Clin Pharmacol. 1976;16:426-432.
  29. Hahn TJ, Birge SJ, Scharp CR, Avioli LV. Phenobarbital-induced alterations in vitamin D metabolism. J Clin Invest. 1972;51:741- 748.
  30. Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med. 1986;59:569-577.
  31. Bikle DD. Drug-induced osteomalacia. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Me- tabolism. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:343-346.
  32. Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llach F. Desferrioxamine therapy in hemodialysis patients with alumi- num-associated bone disease. Kidney Int. 1989;35:1371-1378.
  33. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormone on bone and mineral metabolism. Endocrinol Metab Clin North Am. 1990;19:35-63.
  34. Rosen CJ, Alder RA. Longitudinal changes in lumbar bone den- sity among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab. 1992;75:1531-1534.
  35. Obermayer-Pietsch B, Dobnig H, Warnkross H, et al. Variable bone mass recovery in hyperthyroid bone disease after radioiodine therapy in postmenopausal patients. Maturitas. 2000;35:159- 166.
  36. Obermayer-Pietsch BM, Fruhauf GE, Chararas K, et al. Associa- tion of the vitamin D receptor genotype BB with low bone density in hyperthyroidism. J Bone Miner Res. 2000;15:1950-1955.
  37. Bilezikian JP, Silverberg SJ. Clinical spectrum of primary hyper- parathyroidism. Rev Endocr Metab Disord. 2000;1:237-245.
  38. Dempster DW, Parisien M, Silverberg SJ, et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 1999;84:1562-1566.
  39. Rosen CJ, Rackoff PJ. Emerging anabolic treatment for os- teoporosis. Rheum Dis Clin North Am. 2001;27:215-233, viii.
  40. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post- menopausal women with osteoporosis. N Engl J Med. 2001;344: 1434-1441.
  41. Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimu- lating factor: receptor activator of NF-kappa B ligand. Bone. 1999;25:517-523.
  42. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10- year prospective study of primary hyperparathyroidism with or without parathyroid surgery [published correction appears in N Engl J Med. 2000;342:144].
  43. N Engl J Med. 1999;341:1249-1255.
  44. Parisien MV, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancel- lous bone structure. J Clin Endocrinol Metab. 1990;70:930-938.
  45. Khosla S, Melton LJ III, Wermers RA, Crowson CS, O'Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700-1707.
  46. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321:598-602.
  47. Melton LJ III, Atkinson EJ, O'Fallon WM, Heath H III. Risk of age-related fractures in patients with primary hyperparathyroid- ism. Arch Intern Med. 1992;152:2269-2273.
  48. Larsson K, Lindh E, Lind L, Persson I, Ljunghall S. Increased fracture risk in hypercalcemia: bone mineral content measured in hyperparathyroidism. Acta Orthop Scand. 1989;60:268-270.
  49. Mori S, Shiraki M, Fujimaki H, Ito H. Bone fracture in elderly female with primary hyperparathyroidism: relationship among renal function, vitamin D status and fracture risk. Horm Metab Res. 1987;19:183-185.
  50. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP. Go- nadal status is an important determinant of bone density in ac- romegaly. Clin Endocrinol (Oxf). 1998;48:59-65.
  51. Lund B, Eskildsen PC, Norman AW, Sorensen OH. Calcium and vitamin D metabolism in acromegaly. Acta Endocrinol (Copenh). 1981;96:444-450.
  52. Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C. Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res. 1996;1:377- 382.
  53. Longobardi S, Di Somma C, Di Rella F, et al. Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest. 1998;21:688-693.
  54. Pocock NA, Eisman JA, Dunstan CR, Evans RA, Thomas DH, Huq NL. Recovery from steroid-induced osteoporosis. Ann Intern Med. 1987;107:319-323.
  55. Di Somma C, Colao A, Pivonello R, et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's dis- ease. Clin Endocrinol (Oxf). 1998;48:655-662.
  56. Reddy GK, Stehno-Bittel L, Hamade S, Enwemeka CS. The bio- mechanical integrity of bone in experimental diabetes. Diabetes Res Clin Pract. 2001;54:1-8.
  57. Jehle PM, Jehle DR, Mohan S, Bohm BO. Serum levels of insulin- like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J Endocrinol. 1998;159:297-306.
  58. Crosignani PG, Vegetti W. A practical guide to the diagnosis and management of amenorrhea. Drugs. 1996;52:671-681.
  59. Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1992; 75:692-697.
  60. Kovacs CS, Chik CL. Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels. J Clin Endocrinol Metab. 1995;80:3036-3042.
  61. Stiegler C, Leb G, Kleinert R, et al. Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinemia and correlated to bone density status. J Bone Miner Res. 1995;10:751- 759.
  62. Shaarawy M, El-Dawakhly AS, Mosaad M, El-Sadek MM. Biomarkers of bone turnover and bone mineral density in hyper- prolactinemic amenorrheic women. Clin Chem Lab Med. 1999; 37:433-438.
  63. Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperpro- lactinemic males. J Clin Endocrinol Metab. 1998;83:807-813.
  64. Nielsen S. Epidemiology and mortality of eating disorders. Psychiatr Clin North Am. 2001;24:201-214, vii-viii.
  65. Biller BM, Saxe V, Herzog DB, Rosenthal DI, Holzman S, Klibanski A. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab. 1989;68: 548-554.
  66. Casper RC. The pathophysiology of anorexia nervosa and bulimia nervosa. Annu Rev Nutr. 1986;6:299-316.
  67. Friedman EJ. Neuroendocrine aspects of bulimia. Adolesc Psy- chiatry. 1986;13:422-427.
  68. Rambaut PC, Goode AW. Skeletal changes during space flight. Lancet. 1985;2:1050-1052.
  69. Donaldson CL, Hulley SB, Vogel JM, Hattner RS, Bayers JH, McMillan DE. Effect of prolonged bed rest on bone mineral. Metabolism. 1970;19:1071-1084.
  70. LeBlanc AD, Schneider VS, Evans HJ, Engelbretson DA, Krebs JM. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res. 1990;5:843-850.
  71. Zerwekh JE, Ruml LA, Gottschalk F, Pak CY. The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res. 1998;13:1594-1601.
  72. Palle S, Vico L, Bourrin S, Alexandre C. Bone tissue response to four-month antiorthostatic bedrest: a bone histomorphometric study. Calcif Tissue Int. 1992;51:189-194.
  73. Lueken SA, Arnaud SB, Taylor AK, Baylink DJ. Changes in markers of bone formation and resorption in a bed rest model of weightlessness. J Bone Miner Res. 1993;8:1433-1438.
  74. Melhus H, Michaelsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med. 1998; 129:770-778.
  75. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002;287:47-54.
  76. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000;64:121-129.
  77. Davies FE, Rollinson SJ, Rawstron AC, et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol. 2000;18:2843-2851.
  78. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol. 1997;36:393-396.
  79. Pear BL. Skeletal manifestations of the lymphomas and leuke- mias. Semin Roentgenol. 1974;9:229-240.
  80. Newman AJ, Melhorn DK. Vertebral compression in childhood leukemia. Am J Dis Child. 1973;125:863-865.
  81. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med. 1989;110:430-436.
  82. Lebel E, Itzchaki M, Elstein D, Hadas-Halpern I, Abrahamov A, Zimran A. Skeletal manifestations in Gaucher disease: presenta- tion and treatment. Isr Med Assoc J. 1999;1:267-271.
  83. Pais MJ. Disease states affecting both liver and bone. Radiol Clin North Am. 1980;18:253-267.
  84. Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women. Ann Intern Med. 1993;118:741-742.
  85. Eddy RL. Metabolic bone disease after gastrectomy. Am J Med. 1971;50:442-449.
  86. Mellstrom D, Johansson C, Johnell O, et al. Osteoporosis, meta- bolic aberrations, and increased risk for vertebral fractures after partial gastrectomy. Calcif Tissue Int. 1993;53:370-377.
  87. Deller DJ, Edwards RG, Addison M. Calcium metabolism and the bone after partial gastrectomy: the nature and cause of the bone disorder. Aust Ann Med. 1963;12:295-309.
  88. Meyer D, Stavropolous S, Diamond B, Shane E, Green PH. Os- teoporosis in a North American adult population with celiac dis- ease. Am J Gastroenterol. 2001;96:112-119.
  89. Mora S, Weber G, Barera G, et al. Effect of gluten-free diet on bone mineral content in growing patients with celiac disease. Am J Clin Nutr. 1993;57:224-228.
  90. Kemppainen T, Kroger H, Janatuinen E, et al. Bone recovery after a gluten-free diet: a 5-year follow-up study. Bone. 1999;25:355- 360.
  91. Mora S, Barera G, Beccio S, et al. Bone density and bone metabo- lism are normal after long-term gluten-free diet in young celiac patients. Am J Gastroenterol. 1999;94:398-403.
  92. Buchs N, Helg C, Collao C, et al. Allogeneic bone marrow trans- plantation is associated with a preferential femoral neck bone loss. Osteoporosis Int. 2001;12:880-886. 139. Arlen DJ, Lambert K, Ioannidis G, Adachi JD. Treatment of established bone loss after renal transplantation with etidronate. Transplantation. 2001;71:669-773. 140. Henderson K, Eisman J, Keogh A, et al. Protective effect of short- term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2001;16:565-571. 141. Weber TJ, Quarles LD. Preventing bone loss after renal transplan- tation with bisphosphonates: we can... but should we? [editorial]. Kidney Int. 2000;57:735-737. 142. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int. 1995;57:15-19. 143. Sambrook P, Henderson NK, Keogh A, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2000;15:1818-1824. 144. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352- 364. 145. Sambrook PN, Kelly PJ, Keogh AM, et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant. 1994;13(1, pt 1):116-120. 146. Sambrook PN, Kelly PJ, Fontana D, et al. Mechanisms of rapid bone loss following cardiac transplantation. Osteoporos Int. 1994; 4:273-276. 147. Economides PA, Kaklamani VG, Karavas I, Papaioannou GI, Supran S, Mirel RD. Assessment of physician responses to abnor- mal results of bone densitometry studies. Endocr Pract. 2000; 6:351-356. 148. Fitzpatrick LA, Loftus J, Faurot M, Bolander M. Secondary causes of hip fracture in community-dwelling patients [abstract]. J Bone Miner Res. 2001;16(suppl 1):S273. Abstract SA284.

Cited by

Sorted by citations

Authors
FITZPATRICK, L. A.
Affiliations
Mayo Clinic (US)
Corresponding author
FITZPATRICK, LORRAINE A.
ORCID
FITZPATRICK, LORRAINE A.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2002-05
Volume
77
Issue
5
Pages
453-468
ISSN
0025-6196 (ISSN-L)
DOI
10.1016/s0025-6196(11)62214-3
OpenAlex
W2094994653
Cited by
311
References
5
Citations by year
2026: 5 · 2025: 15 · 2024: 11 · 2023: 21 · 2022: 15 · 2021: 14 · 2020: 18 · 2019: 12 · 2018: 15 · 2017: 15 · 2016: 5 · 2015: 6 · 2014: 12 · 2013: 18 · 2012: 13
FWCI
9.40
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Mayo Clinic Proceedings (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
secondary osteoporosis, bone loss, drug-induced bone loss, endocrine disorders, eating disorders, immobilization, gastrointestinal diseases, biliary tract diseases, kidney disease, cancer, organ transplantation, postmenopausal women, men
MeSH terms
Diabetes Mellitus, Type 1, Endocrine System Diseases, Female, Gastrointestinal Diseases, Humans, Hypervitaminosis A, Immobilization, Kidney Diseases, Male, Neoplasms, Nutrition Disorders, Osteoporosis, Osteoporosis, Postmenopausal, Organ Transplantation, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review